Label-free mass spectrometry assays: maximizing benefits without limitations

Mass spectrometry (MS) remains one of the most powerful label-free technologies for high-throughput screening. That’s why one pharma company enlisted a CRO with MS capabilities to run their next high-throughput screening campaign. However, they soon experienced the caveats of traditional MS approaches, including limited throughput and restrictive conditions, impacting data quality and timelines. Learn how Peapod Bio’s innovative approach to mass spectrometry offered key solutions, including the optimization of the assay based on the target rather than forcing the company to make compromises to utilize the MS instrument, delivering decision-driving data to identify their next drug leads.  

Developing smarter assays to accelerate hit finding programs in small molecule drug discovery

Outsourcing early phase drug discovery research offers several challenges, especially with CROs that offer rigid, one-size-fits-all transactional workflows. This case study describes a young biotech company’s experience initiating a high-throughput screen for their enzyme target using the CRO’s recommended methodology. When the hit rate came back significantly high, the biotech company was forced to spend extra time and resources to triage real results from assay artifacts. When that became cost and time-prohibitive, they contacted Peapod Bio who offered the most collaborative approach to ensure that the assay and resulting data aligned with the company’s goals.

World class compound libraries and assays rapidly identify promising drug leads

One of the most common challenges of running a high-throughput screen is identifying promising series only to have them fail when tested as purified stocks. When a drug discovery company experienced this result, they risked missing critical milestones and falling behind their competition. Learn how Peapod Bio combines innovative and orthogonal assay solutions with world-class compound libraries to offer the most streamlined, decision-driving workflows from assay development to HTS and hit-to-lead optimization.